Summary:
This study is investigating a therapy called cabozantinib for the treatment of advanced hepatocellular carcinoma, the most common form of liver cancer, in adults whose disease has spread or grown after treatment with the medication sorafenib. The main purpose of the CELESTIAL trial is to determine whether cabozantinib can improve patient survival.
Qualified Participants Must:
• - be 18 years or older
- have been diagnosed with advanced hepatocellular carcinoma
- hepatocellular carcinoma has spread or grown following at least one prior cancer medication
• - have received prior sorafenib (Nexavar®
•) treatment - have received up to two prior systemic cancer therapies for hepatocellular carcinoma
- have adequate liver function
Qualified Participants May Receive:
If you qualify and agree to participate in the study, you will be assigned randomly to one of the following groups:
- Group 1: Oral cabozantinib 60 mg tablet once daily
- Group 2: A placebo tablet once daily
Two-thirds of the patients will receive cabozantinib, and one-third will receive a placebo.